ImmunoVec

Executive Summary

ImmunoVec is a San Diego-based biotechnology company pioneering in vivo therapies that precisely engineer targeted cell types using cell type- and cell state-specific transcriptional control elements. Founded in 2019, its delivery-agnostic platform works across viral and non-viral modalities, enabling regulation of therapeutic payloads with high specificity. The company aims to overcome key challenges in gene therapy, such as off-target effects and limited tissue tropism, by leveraging endogenous transcriptional programs. This approach holds potential for safer and more effective treatments across a wide range of genetic and acquired diseases. As a private, early-stage company, ImmunoVec has not yet disclosed specific pipeline programs or funding history. Its immediate focus is likely on advancing preclinical proof-of-concept studies and securing Series A financing to support platform validation and IND-enabling activities. The technology’s broad applicability could attract strategic partnerships with larger biopharma firms seeking innovative gene regulation tools. While the company faces typical early-stage risks, including technical feasibility and capital requirements, its novel approach to cell type-specific control represents a compelling value proposition in the gene therapy landscape.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round60% success
• Q1 2027Preclinical Proof-of-Concept Data from Lead Program50% success
• 2026Research Collaboration with Pharmaceutical Partner40% success